Therefore, insulin-sensitizing agents have been evaluated for the treatment of NAFLD and T2DM, and metformin is an attractive treatment due to its favorable safety profile and potential therapeutic effect [13, 32–34]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.